Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hiroyoshi Takeuchi

Showing results (21-30 of 203) with videos related to

Pageof 21
Sort By:
Journal of Clinical Psychopharmacology|May 31, 2014
Comparing dopamine D(2) receptor occupancies for use in clinical practice: attractive proposition but fraught with pitfallsJimmy Lee, Hiroyoshi Takeuchi, Gary Remington
Schizophrenia Research|April 20, 2016
Consistency between clinician and patient ratings of clozapine-induced side effectsHiroyoshi Takeuchi, Gagan Fervaha, Gary Remington
Therapeutic Advances in Psychopharmacology|October 31, 2022
Pathophysiology, prognosis and treatment of tardive dyskinesiaHiroyoshi Takeuchi, Yasuhiro Mori, Yuichiro Tsutsumi
The Journal of Clinical Psychiatry|August 3, 2022
Tardive Dyskinesia and Long-Acting Injectable Antipsychotics: Analyses Based on a Spontaneous Reporting System Database in JapanFuminari Misawa, Yasuo Fujii, Hiroyoshi Takeuchi
Journal of Clinical Psychopharmacology|February 4, 2021
Can a 4-Month Tolerability Assessment With Paliperidone Palmitate 1-Monthly Prevent Neuroleptic Malignant Syndrome Associated With the 3-Monthly?: Analysis Based on a Spontaneous Reporting System Database in JapanFuminari Misawa, Yasuo Fujii, Hiroyoshi Takeuchi
Journal of Clinical Psychopharmacology|September 15, 2016
Incidence of Antipsychotic-Associated Side Effects: Impact of Clinician Versus Patient Ratings and Change Versus Absolute ScoresHiroyoshi Takeuchi, Gagan Fervaha, Gary Remington
Journal of Clinical Psychopharmacology|January 26, 2024
Real-World Effectiveness of High-Dose Olanzapine and Clozapine for Treatment-Resistant Schizophrenia in Japan: A Retrospective Bidirectional Mirror-Image StudyMaiko Watanabe, Fuminari Misawa, Hiroyoshi Takeuchi
The Journal of Clinical Psychiatry|December 1, 2010
Is there a real difference in severity of tardive dyskinesia between risperidone and olanzapine?Takefumi Suzuki, Hiroyoshi Takeuchi, Koichiro Watanabe
Psychiatry Research|August 21, 2016
Reliability of a patient-reported outcome measure in schizophrenia: Results from back-to-back self-ratingsHiroyoshi Takeuchi, Gagan Fervaha, Gary Remington
Asian Journal of Psychiatry|August 6, 2025
Barriers to transitioning from monthly to 3-monthly paliperidone palmitate formulation: Patient characteristics and physician intentionsFuminari Misawa, Mayu Ogihara, Hiroyoshi Takeuchi
Pageof 21

Showing results (21-30 of 203) with videos related to

Sort By:
Pageof 21
Journal of Clinical Psychopharmacology|May 31, 2014
Comparing dopamine D(2) receptor occupancies for use in clinical practice: attractive proposition but fraught with pitfallsJimmy Lee, Hiroyoshi Takeuchi, Gary Remington
Schizophrenia Research|April 20, 2016
Consistency between clinician and patient ratings of clozapine-induced side effectsHiroyoshi Takeuchi, Gagan Fervaha, Gary Remington
Therapeutic Advances in Psychopharmacology|October 31, 2022
Pathophysiology, prognosis and treatment of tardive dyskinesiaHiroyoshi Takeuchi, Yasuhiro Mori, Yuichiro Tsutsumi
The Journal of Clinical Psychiatry|August 3, 2022
Tardive Dyskinesia and Long-Acting Injectable Antipsychotics: Analyses Based on a Spontaneous Reporting System Database in JapanFuminari Misawa, Yasuo Fujii, Hiroyoshi Takeuchi
Journal of Clinical Psychopharmacology|February 4, 2021
Can a 4-Month Tolerability Assessment With Paliperidone Palmitate 1-Monthly Prevent Neuroleptic Malignant Syndrome Associated With the 3-Monthly?: Analysis Based on a Spontaneous Reporting System Database in JapanFuminari Misawa, Yasuo Fujii, Hiroyoshi Takeuchi
Journal of Clinical Psychopharmacology|September 15, 2016
Incidence of Antipsychotic-Associated Side Effects: Impact of Clinician Versus Patient Ratings and Change Versus Absolute ScoresHiroyoshi Takeuchi, Gagan Fervaha, Gary Remington
Journal of Clinical Psychopharmacology|January 26, 2024
Real-World Effectiveness of High-Dose Olanzapine and Clozapine for Treatment-Resistant Schizophrenia in Japan: A Retrospective Bidirectional Mirror-Image StudyMaiko Watanabe, Fuminari Misawa, Hiroyoshi Takeuchi
The Journal of Clinical Psychiatry|December 1, 2010
Is there a real difference in severity of tardive dyskinesia between risperidone and olanzapine?Takefumi Suzuki, Hiroyoshi Takeuchi, Koichiro Watanabe
Psychiatry Research|August 21, 2016
Reliability of a patient-reported outcome measure in schizophrenia: Results from back-to-back self-ratingsHiroyoshi Takeuchi, Gagan Fervaha, Gary Remington
Asian Journal of Psychiatry|August 6, 2025
Barriers to transitioning from monthly to 3-monthly paliperidone palmitate formulation: Patient characteristics and physician intentionsFuminari Misawa, Mayu Ogihara, Hiroyoshi Takeuchi
Pageof 21